About
Overview
Company Leadership
Science
Technology Platform
Scientific Publications
Pipeline
Overview
CF101
CF102
CF602
Investor Information
Overview
News / Events
Company Information
Financial Information
Stock Information
SEC Filings
Corporate Governance
Shareholders Meetings
Contact Us
Directions
Investor Information
Overview
News / Events
Press Releases
In The News
Research
Events Calendar
Presentations
Email Alerts
Company Information
Profile
Management
IR Contacts
FAQ
Financial Information
Quarterly & Annual Reports
Stock Information
Quote
Charts
Historical Data
SEC Filings
All SEC Filings
Section 16 Filings
Corporate Governance
Board of Directors
Governance Docs
Shareholders Meetings
Email Alerts
IR Contacts
RSS News Feed
Press Releases
All News
By Year:
2019
2018
2017
2016
2015
2014
2013
2012
Oct 15, 2013 7:00 AM EDT
Can-Fite BioPharma's CF101 Drug Selected as one of the "Top Autoimmune/Anti-Inflammatory Disease Projects to Watch" by Elsevier Business Intelligence
Oct 10, 2013 7:00 AM EDT
Can-Fite BioPharma to Present Its Liver Cancer Drug at the 18th World Congress on Advances in Oncology in Greece
Oct 2, 2013 7:00 AM EDT
Can-Fite's Subsidiary OphthaliX to Present at Ophthalmology Futures European Forum
Sep 23, 2013 7:00 AM EDT
Can-Fite CEO Pnina Fishman Interviewed on CorporateProfile.com
Sep 12, 2013 8:19 AM EDT
Can-Fite's Level II ADRs Commence Trading on the U.S. OTC Markets
Sep 3, 2013 1:38 PM EDT
Can-Fite to Present at Rodman & Renshaw Global Investment Conference on September 9, 2013
Aug 28, 2013 11:12 AM EDT
Can-Fite to Initiate a Phase II Study With CF102 in 130 Patients With Advanced Liver Cancer
Feb 5, 2013 9:52 AM EST
Can-Fite Announces Successful Completion of its Public Offering
Nov 13, 2012 10:00 AM EST
Can-Fite BioPharma to Develop a Drug for the Treatment of Sexual Dysfunction
Oct 9, 2012 12:00 AM EDT
Interim Analysis Supports Continuation of Can-Fite's Phase 2/3 Psoriasis Clinical Study with CF101
<< Previous
1...
15
16
17
18
19
20
21
22
23
24
Next >>
Show All
